Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma

As a multi-kinase inhibitor, sorafenib is beneficial in around 30% of hepatocellular carcinoma (HCC) patients; however, HCC patients develop acquired drug resistance quickly. Clinical benefits of sorafenib, in combination with transarterial chemoembolization (TACE), radiotherapy, and other chemodrug...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Yang, Xuran, Xia, Wei, Chen, Lin, Wu, Chuan Xing, Zhang, Cathy C., Olson, Peter, Wang, Xiao Qi
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2018
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201862/
https://ncbi.nlm.nih.gov/pubmed/30405889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26209
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky